AntiP Cancer Research Results

AntiP, antiparasitic: Click to Expand ⟱
Source:
Type:

Antiparasitic Activity - Activity Against Parasitic Organisms

Type: Therapeutic effect / antimicrobial functional outcome

Function: Antiparasitic activity refers to the ability of a compound, extract, drug, or intervention to inhibit the growth, survival, replication, development, or infectivity of parasitic organisms. Depending on the study, this may include protozoa, helminths, or ectoparasites.

Favorable Direction: ↑ Antiparasitic activity = greater inhibition or killing of parasites and is generally favorable.

Unfavorable Direction: ↓ Antiparasitic activity = reduced effectiveness against parasites.
Scientific Papers found: Click to Expand⟱
8038- IVM,    Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
- in-vitro, PC, NA
*AntiP↑, AntiTum↑, ChemoSen↑, TumCP↓, TumCCA↑, cycD1/CCND1↓, mTOR↓, STAT3↑, Apoptosis↑, mtDam↑, ROS↑, MMP↓, OCR↓, MitoP↓,
8036- IVM,    Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway
- in-vitro, ESCC, KYSE-30
*AntiP↑, AntiTum↑, ER Stress↑, TumAuto↑, ATF4↑, CHOP/DDIT3↝, TumCG↓, PERK↑, ROS↑, *toxicity↓, Ca+2↑,
8035- IVM,    Ivermectin and non-parasitic disorders: An update
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
*AntiP↑, angioG↓, *AntiCan↓, mtDam↑, Apoptosis↑, necrosis↑, TumAuto↑, ROS↑, *neuroP↑, *Stroke↝, *cardioP↑,
8031- IVM,    Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment
- Review, Nor, NA
*AntiP↑, Wnt↓, β-catenin/ZEB1↓, PI3K↓, Akt↓, mTOR↓, HH↓, Imm↑, CSCs↓, P-gp/ABCB1↓, Chl↓, angioG↓,
8029- IVM,    Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?
- Review, Var, NA
TumCP↓, Apoptosis↑, Wnt↓, β-catenin/ZEB1↓, Akt↓, mTOR↓, BBB∅, ROS↑, MMP↓, Casp3↓, Casp9↑, TumCCA↑, P53↑, cMyc↓, MMP9↓, HSP27↓, ICD↑, Synergy↑, *AntiP↑,
8027- IVM,    Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
- Review, Var, NA
*AntiP↑, TumCD↑, PAK1↑, TumAuto↑, Casp↑, ICD↑, TCF↝, Hippo↓, Akt↓, mTOR↓, angioG↓, CSCs↓, MMP↓, Cyt‑c↑, Apoptosis↑, BAX↑, P53↑, Bcl-2↓, cycE/CCNE↓, cycD1/CCND1↓, CDK2↓, CDK6↓, CDK4↓, YAP/TEAD↓, TFE3↑, mTORC1↓, mitResp↓, OCR↓, compI↓, MMP↓, ROS↑, SOD2↑, ATP↓, eff↓, mitA↓, P-gp/ABCB1↓, TumVol↓,
8039- IVM,    Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy
- in-vitro, neuroblastoma, SH-SY5Y
*toxicity↑, TumCD↑, ROS↑, mtDam↑, Apoptosis↑, MitoP↑, TumAuto↑, p‑Akt↓, p‑mTOR↓, LC3II↑, Beclin-1/ATG6↑, ATG5↑, PINK1↑, PARK2↑, tumCV↓, MDA↑, SOD↑, Catalase↑, eff↓, MMP↓, BAX↑, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, Cyt‑c↑, Bcl-2↓, proCasp3↓, Bax:Bcl2↑, eff↑, *AntiP↑, *Inflam↓, *AntiDiabetic↑, *AntiViral↑, BBB∅, toxicity↝,
8044- IVM,    Current therapeutic applications and pharmacokinetic modulations of ivermectin
- Review, Var, NA
*AntiP↑, BioAv↓,
8049- IVM,    Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer
- vitro+vivo, BC, NA
*AntiP↑, AntiCan↑, AntiTum↑, PAK1↓, p‑Akt↓, Akt↓, mTOR↓, TumCG↓,
8237- LCA,    Role of Licochalcone A in Potential Pharmacological Therapy: A Review
- Review, Var, NA
*other↝, *Inflam↓, *Bacteria↓, *antiOx↑, *AntiP↑, *neuroP↑, *glucose↝, *lipid-P↓, PKCδ↓, P70S6K↓, Akt↓, ER Stress↑, Apoptosis↑, Ca+2↑, PI3K↓, mTOR↓, Casp3↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑PARP↑, cycD1/CCND1↑, ROS↑, CHOP/DDIT3↑, ERK↑, p38↑, JNK↓, IAP1↓, XIAP↓, survivin↓, cFLIP↓, RIP1↓, EGFR↓, MET↓, HER2/EBBR2↓, p‑4E-BP1↓, PERK↑, eIF2α↑, PD-L1↓, HK2↓, Glycolysis↓, Sp1/3/4↓, FasL↑, MMP↓, ATP↓, TumAuto↑, WEE1↑, P21↑, CDK1↓, TumCCA↑, TumCMig↓, TumCI↓, ABCG2↓, HSP90↓, T-Cell↑, CD4+↑, CD25+↑, FOXP3↑, Imm↝, *Inflam↓, *NF-kB↓, *NRF2↑, *AntiArt↑, *antiAll↑, *MUC5AC↓, *E-sel↓, *CCL11↓,
8253- LCA,    Licochalcone A, a natural chalconoid isolated from Glycyrrhiza inflata root, induces apoptosis via Sp1 and Sp1 regulatory proteins in oral squamous cell carcinoma
- in-vitro, SCC, HSC4
*AntiTum↑, *angioG↓, *AntiP↑, *antiOx↑, *Bacteria↓, *Inflam↓, tumCV↓, Sp1/3/4↓, p27/CDKN1B↑, P21↑, cycD1/CCND1↓, Mcl-1↓, survivin↓, Apoptosis↑,
8208- LCA,    Licochalcone A inhibits PI3K/Akt/mTOR signaling pathway activation and promotes autophagy in breast cancer cells
- in-vitro, BC, MCF7
*Inflam↓, *AntiCan↑, *AntiP↑, LC3II↑, PI3K↓, Akt↓, mTOR↓, Casp3↑, Bcl-2↓, TumAuto↑, Apoptosis↑, tumCV?,
8229- LCA,    Licochalcone A: a review of its pharmacology activities and molecular mechanisms
- Review, Nor, NA
*Inflam↓, *NO↓, *NF-kB↓, *TAC↑, Apoptosis?, TumCCA↑, TumCI↓, TumMeta↓, TumCP↓, MAPK↓, Akt↓, IL6↓, IL8↓, VEGFR2/KDR/Flk1↓, LC3II↑, PI3K↓, mTOR↓, mtDam↑, MMP↓, *NRF2↑, *PGE2↓, *Obesity↓, *SIRT1↑, *AMPK↑, *AntiFungal↑, *AntiP↑, *BMD↑, *GastroP↑,
8203- LGE,  Eug,    Citral and eugenol modulate DNA damage and pro-inflammatory mediator genes in murine peritoneal macrophages
- in-vitro, Nor, NA
*Inflam↓, *antiOx↑, *AntiP↑, *Dose↝, *toxicity↝, *COX2/PTGS2↓, *TNF-α↓,
8434- OM,    Traditional use, phytochemistry, toxicology, and pharmacology of Origanum majorana L
- Review, Var, NA
*Bacteria↓, *AntiFungal↑, *antiOx↑, *AntiP↑, *AntiDiabetic↑, *AntiCan↑, *RenoP↑, *Inflam↓, *Analgesic↑, *antiPy↑, *antiM↑, *Ingr↝, *Ingr↝, *creat↓, *Urea↓, *uricA↓, *BUN↓, *ALAT↓, *AST↓, *ALP↓, *Catalase↑, *SOD↑, *GSTA1↑,

Showing Research Papers: 1 to 15 of 15

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   MDA↑, 1,   ROS↑, 7,   SOD↑, 1,   SOD2↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↓, 1,   mitResp↓, 1,   mtDam↑, 4,   OCR↓, 2,   PINK1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ATP↓, 2,   Glycolysis↓, 1,   HK2↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis?, 1,   Apoptosis↑, 8,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Casp↑, 1,   Casp3↓, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   proCasp3↓, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 3,   FasL↑, 1,   IAP1↓, 1,   ICD↑, 2,   Mcl-1↓, 1,   necrosis↑, 1,   p38↑, 1,   survivin↓, 2,   TumCD↑, 2,   XIAP↓, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 7,   p‑Akt↓, 2,   EGFR↓, 1,   ERK↑, 1,   HER2/EBBR2↓, 1,   Hippo↓, 1,   JNK↓, 1,   MAPK↓, 1,   mTOR↓, 8,   p‑mTOR↓, 1,   P70S6K↓, 1,   PI3K↓, 4,   PKCδ↓, 1,   RIP1↓, 1,   Sp1/3/4↓, 2,   STAT3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 1,   cMyc↓, 1,   TFE3↑, 1,   tumCV?, 1,   tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   CHOP/DDIT3↝, 1,   eIF2α↑, 1,   ER Stress↑, 2,   HSP27↓, 1,   HSP90↓, 1,   PERK↑, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6↑, 1,   LC3II↑, 3,   MitoP↓, 1,   MitoP↑, 1,   PARK2↑, 1,   TumAuto↑, 6,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 2,   cl‑PARP↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 1,   CDK6↓, 1,   cycD1/CCND1↓, 3,   cycD1/CCND1↑, 1,   cycE/CCNE↓, 1,   mitA↓, 1,   P21↑, 2,   p27/CDKN1B↑, 1,   TumCCA↑, 4,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,   CSCs↓, 2,   HH↓, 1,   mTORC1↓, 1,   TumCG↓, 2,   TumCP↓, 3,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

Ca+2↑, 2,   Chl↓, 1,   MET↓, 1,   MMP9↓, 1,   PAK1↓, 1,   PAK1↑, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumMeta↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB∅, 2,   MMP↓, 7,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↑, 1,   CD4+↑, 1,   FOXP3↑, 1,   IL6↓, 1,   IL8↓, 1,   Imm↑, 1,   Imm↝, 1,   PD-L1↓, 1,   T-Cell↑, 1,   TCF↝, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 1,   ChemoSen↑, 1,   eff↓, 2,   eff↑, 1,   P-gp/ABCB1↓, 2,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 3,   toxicity↝, 1,   TumVol↓, 1,  
Total Targets: 132

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   Catalase↑, 1,   lipid-P↓, 1,   NRF2↑, 2,   SOD↑, 1,   TAC↑, 1,   uricA↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 1,   glucose↝, 1,   SIRT1↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   E-sel↓, 1,   NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,   MUC5AC↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCL11↓, 1,   COX2/PTGS2↓, 1,   Inflam↓, 8,   NF-kB↓, 2,   PGE2↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   GSTA1↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   BMD↑, 1,   BUN↓, 1,   creat↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Analgesic↑, 1,   antiAll↑, 1,   AntiArt↑, 1,   AntiCan↓, 1,   AntiCan↑, 2,   AntiDiabetic↑, 2,   antiM↑, 1,   antiPy↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   neuroP↑, 2,   Obesity↓, 1,   RenoP↑, 1,   Stroke↝, 1,   toxicity↓, 1,   toxicity↑, 1,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 2,   AntiP↑, 15,   AntiViral↑, 1,   Bacteria↓, 3,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 2,  
Total Targets: 54

Scientific Paper Hit Count for: AntiP, antiparasitic
9 Ivermectin
4 Licochalcone A
1 Lemongrass Extract/Citral
1 Eugenol
1 Marjoram (Origanum majorana)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:1749  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page